Docket #0262 Date Filed: 02/03/2026

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	)	Chapter 11
Apple Tree Life Sciences, Inc., *et al.*,[1]	)	Case No. 25-12177 (LSS)
Debtors.	)	(Jointly Administered)

SCHEDULES OF ASSETS AND LIABILITIES FOR ATP LIFE SCIENCE VENTURES, L.P. CASE NO. 25-12178

[1] The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Squar Incorporated (8493). The location of the Debtors' service address in thes New York, NY 10169.

25121772602030000000000010
Filed January 30, 2026

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	Chapter 11
Apple Tree Life Sciences, Inc., *et al.*,[1]	Case No. 25-12177 (LSS)
Debtors.	(Jointly Administered)

GLOBAL NOTES AND STATEMENT OF LIMITATIONS, METHODOLOGY, AND DISCLAIMERS REGARDING THE DEBTORS' SCHEDULES OF ASSETS AND LIABILITIES AND STATEMENTS OF FINANCIAL AFFAIRS

General

Apple Tree Life Sciences, Inc. ("ATLS"), and its debtor affiliates, as debtors and debtors in possession in the above-captioned chapter 11 cases (collectively, the "Debtors"), are filing their respective *Schedules of Assets and Liabilities* (each, a "Schedule," and collectively, the "Schedules") and *Statements of Financial Affairs* (each, a "Statement," and collectively with the Schedules, the "Schedules and Statements") with the United States Bankruptcy Court for District of Delaware (the "Bankruptcy Court") pursuant to section 521 of title 11 of the United States Code (the "Bankruptcy Code"), rule 1007 of the Federal Rules of Bankruptcy Procedure (the "Bankruptcy Rules"), and Rule 1007-1 of the Local Rules of the United States Bankruptcy Court for the District of Delaware (the "Local Rules").

These global notes and statements of limitations, methodology and disclaimers regarding the Debtors' Schedules and Statements (the "Global Notes") pertain to, are incorporated by reference in, and comprise an integral part of, all of the Schedules and Statements, and should be referred to, and referenced in connection with, any review of the Schedules and Statements.[2]

The Schedules and Statements are unaudited and reflect the Debtors' reasonable efforts to report certain financial information of each Debtor on a stand-alone, unconsolidated basis. These Schedules and Statements neither purport to represent financial statements prepared in

[1] The Debtors in these chapter 11 cases, together with the last four digits of each Debtor's federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Square Therapeutics, Inc. (4503); and Nereid Therapeutics Incorporated (8493). The location of the Debtors' service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.

[2] These Global Notes supplement, and are in addition to, any specific notes contained in each Debtor's Schedules or Statements. The fact that the Debtors prepared these Global Notes with respect to any of the individual Debtor's Schedules and Statement and not to those of another should not be interpreted as a decision by the Debtors to exclude the applicability of such Global Note to any of the Debtors' other Schedules and Statements, as appropriate.

accordance with Generally Accepted Accounting Principles in the United States ("GAAP"), nor are they intended to be fully reconciled with the financial statements of each Debtor.

In preparing the Schedules and Statements, the Debtors relied on financial data derived from their books and records that were available at the time of such preparation. Although the Debtors have made commercially reasonable efforts to ensure the accuracy and completeness of the Schedules and Statements, subsequent information or discovery may result in material changes to the Schedules and Statements. As a result, inadvertent errors or omissions may exist. Accordingly, the Debtors and their directors, managers, officers, agents, attorneys and financial advisors do not guarantee or warrant the accuracy or completeness of the data that is provided herein, and shall not be liable for any loss or injury arising out of or caused in whole or in part by the acts, errors, or omissions, whether negligent or otherwise, in procuring, compiling, collecting, interpreting, reporting, communicating, or delivering the information contained herein or the Schedules and Statements. In no event shall the Debtors or their directors, managers, officers, agents, attorneys and financial advisors be liable to any third party for any direct, indirect, incidental, consequential, or special damages (including, but not limited to, damages arising from the disallowance of a potential claim against the Debtors or damages to business reputation, lost business, or lost profits), whether foreseeable or not and however caused, even if the Debtors or their directors, managers, officers, agents, attorneys, and financial advisors are advised of the possibility of such damages.

The Schedules and Statements have been signed by Perry M. Mandarino, the Debtors' Chief Restructuring Officer. Mr. Mandarino is an authorized signatory for each of the Debtors. In reviewing and signing the Schedules and Statements, Mr. Mandarino relied upon the efforts, statements, advice, and representations of personnel of the Debtors and the Debtors' advisors and other professionals. Given the scale of the Debtors' businesses, Mr. Mandarino has not (and practically could not have) personally verified the accuracy of each statement and representation in the Schedules and Statements, including, but not limited to, statements and representations concerning amounts owed to creditors, classification of such amounts, and creditor addresses.

Subsequent receipt of information or an audit may result in material changes in financial data requiring amendment of the Schedules and Statements. Accordingly, the Schedules and Statements remain subject to further review and verification by the Debtors. The Debtors reserve their right to amend the Schedules and Statements from time-to-time as may be necessary or appropriate; provided, that the Debtors, their agents, and their advisors expressly do not undertake any obligation to update, modify, revise, or recategorize the information provided herein or to notify any third party should the information be updated, modified, revised, or recategorized, except to the extent required by applicable law.

The Schedules, Statements, and Global Notes should not be relied upon by any persons for information relating to current or future financial conditions, events, or performance of any of the Debtors.

Global Notes and Overview of Methodology

1. **Description of the Cases.** The Debtors commenced these voluntary cases under chapter 11 of the Bankruptcy Code on December 9 and 15, 2025 and January 1 and 15, 2026 (collectively, the "Petition Dates," and each, a "Petition Date"). The Debtors are authorized to operate their businesses and manage their properties as debtors in possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code. The Debtors' chapter 11 cases are being jointly administered for procedural purposes only pursuant to Bankruptcy Rule 1015(b). *See* Docket Nos. 69, 178 & 200. On January 20, 2026, the United States Trustee for the District of Delaware (the "U.S. Trustee") appointed an Official Committee of Unsecured Creditors pursuant to section 1102(a)(1) of the Bankruptcy Code (the "UCC") [Docket No. 194]. Notwithstanding the joint administration of the Debtors' cases for procedural purposes, each Debtor has filed, or will file, its own Schedules and Statements.

2. **Global Notes Control.** Disclosure of information in one or more Schedules, one or more Statements, or one or more exhibits or attachments to the Schedules or Statements, even if incorrectly placed, shall be deemed to be disclosed in the correct Schedules, Statements, exhibits, or attachments. In the event that the Schedules or Statements differ from any of the Global Notes, the Global Notes shall control.

3. **Reservation of Rights.** Commercially reasonable efforts have been made to prepare and file complete and accurate Schedules and Statements; however, as noted above, inadvertent errors or omissions may exist. The Debtors reserve all rights to amend and supplement the Schedules and Statements as may be necessary or appropriate but do not undertake any obligation to do so, except as required by applicable law. Nothing contained in the Schedules, Statements, or Global Notes shall constitute a waiver of rights with respect to these chapter 11 cases, including, but not limited to, any rights or claims of the Debtors against any third party or issues involving substantive consolidation, defenses, statutory or equitable subordination, and/or causes of action arising under the provisions of chapter 5 of the Bankruptcy Code or any other relevant applicable bankruptcy or non-bankruptcy laws to recover assets or avoid transfers. Any specific reservation of rights contained elsewhere in the Global Notes does not limit in any respect the general reservation of rights contained in this paragraph.

    a. **No Admission.** Nothing contained in the Schedules and Statements is intended as, or should be construed as, an admission or stipulation of the validity of any claim against any Debtors, any assertion made therein or herein, or a waiver of any of the Debtors' rights to dispute any claim or assert any cause of action or defense against any party.

    b. **Claims Listing and Descriptions**. The listing of a claim does not constitute an admission of liability by the Debtors, and the Debtors reserve the right to amend the Schedules and Statements accordingly. Any failure to designate a claim listed on the Schedules and Statements as "disputed," "contingent," or "unliquidated" does not constitute an admission by the Debtors that such amount is not "disputed," "contingent," or "unliquidated." The Debtors reserve the right to dispute and to assert

setoff rights, counterclaims, and defenses to any claim reflected on their Schedules and Statements on any grounds, including, but not limited to, amount, liability, priority, status, and classification, and to otherwise subsequently designate any claim as "disputed," "contingent," or "unliquidated."

c. **Recharacterization.** The Debtors have made reasonable efforts to correctly characterize, classify, categorize, and designate the claims, assets, executory contracts, unexpired leases, and other items reported in the Schedules and Statements. Nevertheless, due to the complexity of the Debtors' businesses, the Debtors may not have accurately characterized, classified, categorized, or designated certain items and/or may have omitted certain items. Accordingly, the Debtors reserve all of their rights to recharacterize, reclassify, recategorize, or redesignate items reported in the Schedules and Statements at a later time as necessary or appropriate, including, without limitation, whether contracts or leases listed herein were deemed executory or unexpired as of the Petition Date and remain executory and unexpired post-petition.

d. **Classifications.** The listing of a claim (i) on Schedule D as "secured," (ii) on Schedule E/F as either "priority," or "unsecured priority," or (iii) listing a contract or lease on Schedule G as "executory" or "unexpired" does not constitute an admission by the Debtors of the legal rights of the claimant or contract counterparty, or a waiver of the Debtors' rights to recharacterize or reclassify such claim or contract pursuant to a schedule amendment, claim objection or otherwise. Moreover, although the Debtors may have scheduled claims of various creditors as secured claims for informational purposes, no current valuation of the Debtors' assets in which such creditors may have a security interest has been undertaken. Except as provided in an order of the Court, the Debtors reserve all rights to dispute and challenge the secured nature or amount of any such creditor's claims or the characterization of the structure of any transaction, or any document or instrument related to such creditor's claim.

e. **Estimates and Assumptions.** To prepare these Schedules and Statements and report information on a legal entity basis, the Debtors were required to make certain reasonable estimates and assumptions with respect to the reported amounts of assets and liabilities, the amount of contingent assets and contingent liabilities as of the Petition Date. Actual results could differ from such estimates. The Debtors reserve all rights to amend the reported amounts of assets and liabilities to reflect changes in those estimates or assumptions.

f. **Causes of Action.** Despite reasonable efforts, the Debtors may not have identified and/or set forth all of their causes of action (filed or potential) against third parties as assets in their Schedules and Statements, including, without limitation, avoidance actions arising under chapter 5 of the Bankruptcy Code and actions under other relevant bankruptcy and non-bankruptcy laws to recover assets. The Debtors reserve all rights with respect to any claim, controversy, demand, right, action, suit, obligation, liability, debt, account, defense, offset, power, privilege, license, lien, indemnity, guaranty, interest, damage, remedy, cause of action, proceeding, agreement, or franchise of any kind or character whatsoever, whether known or unknown, foreseen or unforeseen, existing or hereinafter arising, contingent or non-

contingent, liquidated or unliquidated, secured or unsecured, assertable, directly or derivatively, matured or unmatured, suspected or unsuspected, whether arising before, on, or after the Petition Date, in contract, in tort, at law, in equity, or otherwise. Causes of action also include: (a) all rights of setoff, counterclaim, or recoupment and claims under contracts or for breaches of duties imposed by law or in equity; (b) any claim based on or relating to, or in any manner arising from, in whole or in part, tort, breach of contract, breach of fiduciary duty, violation of local, state, federal, or foreign law, or breach of any duty imposed by law or in equity, including, without limitation, securities laws, negligence, and gross negligence; (c) the right to object to or otherwise contest claims or interests; (d) claims pursuant to sections 362 or chapter 5 of the Bankruptcy Code; (e) such claims and defenses as fraud, mistake, duress, and usury, and any other defenses set forth in section 558 of the Bankruptcy Code; and (f) any avoidance actions arising under chapter 5 of the Bankruptcy Code or under similar local, state, federal, or foreign statutes and common law, including, without limitation, fraudulent transfer laws, and neither the Global Notes nor the Schedules and Statements shall be deemed a waiver of any such claims, causes of action, or avoidance actions, or in any way prejudice or impair the assertion of such claims or causes of action.

g. Intellectual Property Rights. Exclusion of certain intellectual property on the Statements and Schedules shall not be construed to be an admission that such intellectual property rights have been abandoned, have been terminated, or otherwise have expired by their terms, or have been assigned or otherwise transferred pursuant to a sale, acquisition, or other transaction. Conversely, inclusion of certain intellectual property on the Statements and Schedules shall not be construed to be an admission that such intellectual property rights have not been abandoned, have not been terminated, or otherwise have not expired by their terms, or have not been assigned or otherwise transferred pursuant to a sale, acquisition, or other transaction. The Debtors have made every effort to attribute intellectual property to the rightful Debtor owner, however, in some instances, intellectual property owned by one Debtor may, in fact, be owned by another. Accordingly, the Debtors reserve all of their rights with respect to the legal status of any and all intellectual property rights.

h. Insiders. The Debtors have attempted to include all payments made on or within twelve months before the Petition Date to any individual (and their relatives) or entity who, in the Debtors' good faith belief, may be deemed an "insider" as set forth in section 101(31) of the Bankruptcy Code. As to each Debtor, an individual or entity is designated as an "insider" for the purposes of the Schedules and Statements if such individual or entity, based on the totality of the circumstances, has at least a controlling interest in, or exercises sufficient authority over, the Debtor so as to dictate corporate policy and the disposition of corporate assets.

The listing or omission of a party as an "insider" for the purposes of the Schedules and Statements is for informational purposes and is not intended to be nor should be construed as an admission that those parties are insiders for purposes of section 101(31) of the Bankruptcy Code. Information regarding the individuals or entities listed as insiders in the Schedules and Statements may not be used for: (a) the

purposes of determining (i) control of the Debtors; (ii) the extent to which any individual or entity exercised management responsibilities or functions; (iii) corporate decision-making authority over the Debtors; or (iv) whether such individual or entity (or the Debtors) could successfully argue that they are not an insider under applicable law, including the Bankruptcy Code and federal securities laws, or with respect to any theories of liability or (b) any other purpose. Furthermore, certain of the individuals or entities identified as insiders may not have been insiders for the entirety of the twelve-month period before the Petition Date. The Debtors reserve all rights with respect thereto.

4. Methodology

a. Basis of Presentation. These Schedules and Statements neither purport to represent financial statements prepared in accordance with GAAP nor are they intended to fully reconcile to the financial statements prepared by the Debtors. Information contained in the Schedules and Statements has been derived from the Debtors' books and records and historical financial statements.

The Debtors attempted to attribute the assets and liabilities, certain required financial information, and various cash disbursements to the proper Debtor entity. However, due to limitations within Debtors' accounting systems, it is possible that not all assets, liabilities or amounts of cash disbursements have been recorded with the correct legal entity on the Schedules and Statements. Accordingly, the Debtors reserve all rights to supplement and/or amend the Schedules and Statements in this regard.

Given, among other things, the uncertainty surrounding the collection, ownership, and valuation of certain assets and the amount and nature of certain liabilities, a Debtor may report more assets than liabilities. Such report shall not constitute an admission that such Debtor was solvent on the Petition Date or at any time prior to or after the Petition Date. Likewise, a Debtor reporting more liabilities than assets shall not constitute an admission that such Debtor was insolvent on the Petition Date or at any time prior to or after the Petition Date. For the avoidance of doubt, nothing contained in the Schedules and Statements is indicative of the Debtors' enterprise value. The Schedules and Statements contain unaudited information that is subject to further review and potential adjustment.

b. Reporting Date. Unless otherwise noted, the Schedules and Statements generally reflect the Debtors' books and records as of the Petition Date.

c. Confidentiality or Sensitive Information. There may be instances in which certain information in the Schedules and Statements intentionally has been redacted due to concerns about the privacy of the Debtors' employees and vendors (*e.g.*, home addresses). The alterations will be limited to only what is necessary to protect the Debtor or the applicable third party. The Debtors may also be authorized or required to redact certain information from the public record pursuant to orders of the Court authorizing the Debtors to redact, seal, or otherwise protect such information from public disclosure.

d. Duplication. Certain of the Debtors' assets, liabilities, and prepetition payments may properly be disclosed in response to multiple parts of the Statements and Schedules. To the extent these disclosures would be duplicative, the Debtors have determined to only list such assets, liabilities, and prepetition payments once.

e. Net Book Value of Assets. In many instances, current market valuations are not maintained by or readily available to the Debtors. It would be prohibitively expensive, unduly burdensome, and an inefficient use of estate resources for the Debtors to obtain current market valuations for all assets. As such, unless otherwise indicated, net book values are as of the Petition Date. When necessary, the Debtors have indicated that the value of certain assets is "Unknown" or "Undetermined." The description of an amount as "unknown" or "undetermined" is not intended to reflect upon the materiality of such amount. Amounts ultimately realized may vary materially from net book value (or other value so ascribed). Accordingly, the Debtors reserve all rights to amend, supplement, and adjust the asset values set forth in the Schedules and Statements. Assets that have been fully depreciated or that were expensed for accounting purposes either do not appear in these Schedules and Statements or are listed with a zero-dollar value, as such assets have no net book value. The omission of an asset from the Schedules and Statements does not constitute a representation regarding the ownership of such asset, and any such omission does not constitute a waiver of any rights of the Debtors with respect to such asset. Nothing in the Debtors' Schedules and Statements shall be, or shall be deemed to be, an admission that any Debtor was solvent or insolvent as of the Petition Date or any time prior to the Petition Date.

f. Currency. All amounts shown in the Schedules and Statements are in U.S. Dollars, unless otherwise indicated.

g. Payment of Prepetition Claims Pursuant to Payment Orders. Following the Petition Date, the Court entered various orders authorizing the Debtors to, among other things, pay certain prepetition claims, including without limitation: insurance obligations; employee wages, salaries, and related items (including, but not limited to, employee benefit programs and contractor wage obligations); and other obligations (collectively, the "Payment Orders"). Accordingly, certain of these liabilities may have been, or will be, satisfied in accordance with the Payment Orders. Where the Schedules list creditors and set forth the Debtor's scheduled amount of such claims, such scheduled amounts reflect amounts owed as of the Petition Date. The Debtors reserve the right to amend and/or supplement the Schedules and Statements to reflect payments made pursuant to an order of the Court.

h. Other Paid Claims. To the extent the Debtors have reached any post-petition settlement with a vendor or other creditor, the terms of such settlement will prevail, supersede amounts listed in the Schedules and Statements, and shall be enforceable by all parties, subject to any necessary Court approval. To the extent the Debtors pay any of the claims listed in the Schedules and Statements pursuant to any orders entered by the Court, the Debtors reserve all rights to amend and supplement the Schedules and Statements and take other action, such as filing claims objections, as is

necessary and appropriate to avoid overpayment or duplicate payment for such liabilities.

i. **Leases.** Nothing in the Schedules and Statements is, or shall be construed to be, an admission as to the determination of the legal status of any lease (including whether any lease is a true lease, a financing arrangement, or a real property interest), and the Debtors reserve all rights with respect to such issues.

j. **Liens.** The inventories, property, and equipment listed in the Statements and Schedules are presented without consideration of any asserted mechanics', materialmen, or similar liens that may attach (or have attached) to such inventories, property, and equipment, and the Debtors reserve all of their rights with respect to such liens (if any).

k. **Allocation of Liabilities.** The Debtors, in consultation with their advisors, have sought to allocate liabilities between the prepetition and post-petition periods based on the information and research that was conducted in connection with the preparation of the Schedules and Statements. As additional information becomes available and further research is conducted, the allocation of liabilities between prepetition and post-petition periods may change. The Debtors reserve the right to amend and/or supplement the Schedules and Statements as they deem appropriate in this regard.

l. **Totals.** All totals that are included in the Schedules and Statements represent totals of all the known amounts included in the Schedules and Statements and exclude items identified as "unknown" or "undetermined." If there are unknown or undetermined amounts, the actual totals may be materially different from the listed totals. The description of an amount as "unknown" or "undetermined" is not intended to reflect upon the materiality of such amount.

m. **Unliquidated Claim Amounts.** Claim amounts that could not be readily quantified by the Debtors are scheduled as "unliquidated."

n. **Credits and Adjustments.** The claims of individual creditors for, among other things, goods, products, services, and taxes are listed as the amounts entered on the Debtors' books and records and may either (i) not reflect credits, allowances, or other adjustments due from such creditors to the Debtors or (ii) be net of accrued credits, allowances, rebates, trade debits, or other adjustments that are actually owed by a creditor to the Debtors on a post-petition basis on account of such credits, allowances, or other adjustments earned from prepetition payments and post-petition payments, if applicable. The Debtors reserve all of their rights with regard to such credits, allowances, and other adjustments, including but not limited to, the right to assert claims objections and/or setoffs with respect to the same.

o. Claims of Third-Party Related Entities. While the Debtors have made every effort to properly classify each claim listed in the Schedules as being either disputed or undisputed, liquidated or unliquidated, and contingent or noncontingent, the Debtors have not been able to fully reconcile all payments made to certain third parties and their related entities on account of the Debtors' obligations thereto. Therefore, to the extent that the Debtors have classified their estimate of claims of a creditor as disputed, all claims of such creditor's affiliates listed in the Schedules and Statements shall similarly be considered as disputed, whether or not they are designated as such.

Notes Specific to Schedules of Assets and Liabilities

Schedule A/B: Assets

Part 1 – Cash and Cash Equivalents

(a) Question 3 – Checking, Savings, Money Market, or Financial Brokerage Accounts. Further details with respect to the Debtors' cash management system and bank accounts are also provided in the *Final Order (I) Authorizing the Debtors to (A) Continue to Operate Their Cash Management System and (B) Honor Certain Pre-Petition Obligations Related Thereto, and (II) Granting Related Relief* [Docket No. 189] and the *Order (I) Directing Joint Administration of Additional Chapter 11 Cases and (II) Extending Certain Relief Granted to the Original Debtors* [Docket No. 200].

Part 2 – Deposits and Prepayments

(a) Question 8 – Prepayments. In the ordinary course of business, Debtor ATP Life Science Ventures, L.P. advances a bi-annual management fee (the "Management Fee") to Debtor Apple Tree Life Sciences, Inc. to pay for operating costs and management expenses. The Management Fee is not identified on the Schedules and Statements because payment of any further Management Fees is subject to further orders of the Court. The Debtors may have inadvertently omitted deposits and conversely may have reported deposits that are no longer outstanding. The Debtors reserve their rights, but are not required, to amend the Schedules and Statements if deposits are incorrectly identified. Certain prepayments may be reflected on an amortized basis to the extent recorded in the Debtors' books and records as such.

Part 4 – Investments

(a) Question 15 – Non-Publicly Traded Stock and Interests in Incorporated and Unincorporated Businesses, Including any Interest in an LLC, Partnership, or Joint Venture. Schedule A/B 15 includes Debtor ATP Life Science Ventures, L.P.'s ownership interest in the debtor and non-debtor portfolio companies. The value of the Debtor's interest listed therein is based on the Debtor's audited financial statements as of December 31, 2024 and may not be reflective of current values as to which the Debtors reserve all rights.

Part 11 – All Other Assets

(a) Question 73 – Interests in Insurance Policies or Annuities. A list of the Debtor's insurance policies can be found in the *Debtors' Motion for Entry of an Order (I) Authorizing the Debtors to (A) Pay Their Obligations Under Prepetition Insurance Policies, (B) Continue to Pay Certain Brokerage Fees, (C) Renew, Supplement, Modify or Purchase Insurance Coverage, and (II) Granting Related relief* [Docket No. 106] and the *Debtors' Motion for an Order (I) Directing Joint Administration of Additional Chapter 11 Case and (II) Extending Certain Relief Granted to the Original Debtors* [Docket No. 162]. Accordingly, the Debtors have not duplicated such information in Schedule A/B 73.

(b) Question 75 – Other Contingent and Unliquidated Claims or Causes of Action. Certain Debtors are party to two matters before the Delaware Court of Chancery from which they stand to receive judgment payouts. Debtor ATP Life Science Ventures, L.P. is a potential beneficiary of an approximately $370 million Chancery Court damages award and judgment in *Shareholder Representative Services LLC v. Alexion Pharmaceuticals, Inc.*, No. 2020-1069-MTZ. However, this is not yet a final judgment and as such has been listed in the Schedules and Statements as a contingent and undetermined claim or cause of action. Additionally, the Debtors were awarded $97 million in specific performance in *ATP III GP, Ltd. v. Rigmora Biotech Investor One LP*, No. 2025-0607. The money transferred to the Debtors on account of that judgment is not readily available to them as described in the *Order Authorizing the Debtors to Open New Segregated Bank Account* [Docket No. 79], and therefore is not listed in the Schedules and Statements.

(c) Question 77 – Other Property of Any Kind not Already Listed. The value of the intercompany balances listed on Schedule A/B 77 are listed as of the Petition Date.

Schedule D: Creditors Who Have Claims Secured by Property

Except as otherwise agreed pursuant to a stipulation or order entered by the Bankruptcy Court, the Debtors reserve their rights to dispute or challenge the validity, perfection, or immunity from avoidance of any lien purported to be granted or perfected in any specific asset to a secured creditor listed on Schedule D of any Debtor. Moreover, although the Debtors may have scheduled claims of various creditors as secured claims, the Debtors reserve all rights to dispute or challenge the secured nature of any such creditor's claim or the characterization of the structure of any such transaction or any document or instrument (including, without limitation, any intercompany agreement) related to such creditor's claim. Further, the listing of a claim as secured is not an admission as to the validity of any lien. The descriptions provided in Schedule D are intended only to be a summary. Reference to the applicable lease agreements and related documents is necessary for a complete description of the collateral and the nature, extent, and priority of any liens. Nothing in these Global Notes or the Schedules and Statements shall be deemed a modification or interpretation of the terms of such agreements.

Schedule E/F: Creditors Who Have Unsecured Claims

The liabilities identified in Schedule E/F, Part 2, are derived from the Debtors' books and records. The Debtors made reasonable attempts to set forth their unsecured obligations, although the actual amount of claims against the Debtors may vary from those liabilities represented on Schedule E/F, Part 2. The listed liabilities may not reflect the correct amount of any unsecured creditor's allowed claims or the correct amount of all unsecured claims. The amounts listed on schedule E/F may not reflect any right of setoff or recoupment, and the Debtors reserve any such setoff or recoupment rights. Some of the scheduled liabilities may be unknown, contingent and/or unliquidated at this time. In such cases, the amounts may be listed as "Undetermined." Accordingly, the Schedules and the Statements may not equal the aggregate value of the Debtors' total liabilities as noted on any previously issued financial statements.

In addition to nonpriority unsecured claims by third-party claimants, intercompany payables between and among the Debtors and non-Debtor affiliates are also reported on Schedule E/F, Part 2.

Schedule G: Unexpired Leases and Executory Contracts

The contracts, agreements and leases listed on Schedule G may have expired or may have been modified, amended or supplemented from time to time by various amendments, restatements, waivers, estoppels, certificates, letters, memoranda or other documents, instruments and agreements that may not be listed on Schedule G, despite the Debtor's use of reasonable efforts to identify such documents. Certain of the executory contracts and unexpired leases listed on Schedule G may contain certain renewal options, guarantees of payment, options to purchase, rights of first refusal, and other miscellaneous rights, which are not set forth separately on Schedule G. In addition, the Debtor may have entered into various other types of agreements in the ordinary course of business, such as subordination, non disturbance and attornment agreements, supplemental agreements, amendments/letter agreements, title agreements and confidentiality agreements. Such documents may not be set forth on Schedule G. Certain of the executory contracts may not have been memorialized and may be subject to dispute. Certain of the executory contracts or unexpired leases listed in Schedule G may include one or more ancillary documents, including but not limited to any underlying assignment and assumption agreements, amendments, supplements, full and partial assignments, renewals and partial releases. Executory contracts that are oral in nature, if any, have not been included on Schedule G. To the extent the Bankruptcy Court determines a particular contract is executory, the Debtor will amend Schedule G to add that contract, as necessary or appropriate.

Omission of a contract or agreement from Schedule G does not constitute an admission that such omitted contract or agreement is not an executory contract or unexpired lease. The Debtor's rights under the Bankruptcy Code with respect to any such omitted contracts or agreements are not impaired by the omission.

Notes Specific to Statements of Financial Affairs

Part 1, Question 1 – Income. Revenue has been presented from January 1, 2025, through the Petition Date.

Part 2, Question 3 – Payments or Transfers to Certain Creditors. The Debtors have responded in detailed format by listing the payments by vendor. The response does not include any transfers to the Debtors' bankruptcy professionals for services related to these chapter 11 cases (such transfers are disclosed under Part 6, Question 11).

Part 2, Question 4 – Payments or Other Transfers of Property Made Within 1 Year Before the Petition Date That Benefited Any Insider. Prior to the Petition Date, in the ordinary course of business, the Debtors engaged in intercompany transactions among the Management Debtors and Portfolio Companies (the "Intercompany Funding"). Intercompany Funding payments made within one (1) year before the Petition Date are reported on Statement 4. The listing of any amounts with respect to such Intercompany Funding is not, and should not be construed as, an admission of the characterization of such balances as debt, equity, or otherwise.

Part 6, Question 11 – Payments Related to Bankruptcy. The Debtors have used reasonable efforts to identify payments for services of any entities who provided consultation concerning debt counseling or restructuring services, relief under the Bankruptcy Code or preparation of a petition in bankruptcy within one year immediately before the Petition Date, which are identified in the Debtors' response to Part 6, Question 11 of the Statements. Additional information regarding the Debtors' retention of professional service firms is more fully described in the individual retention applications for those firms and any related orders. *See* Docket Nos. 22, 131, 132, 133, 134, 137, & 148.

Part 13, Question 25 – Other Businesses in Which the Debtor Has or Has Had an Interest. The Debtors have used reasonable efforts to identify the Employer Identification Numbers for the entities listed on Statement 25. However, the Debtors no longer hold an interest in certain entities disclosed on Statement 25 and could not reasonably ascertain such entities' Employer Identification Numbers.

Part 13, Question 28 – Officers, Directors, General Partners, Members in Control, Controlling Shareholders, or Other People in Control of the Debtor as of the Petition Date. The ownership interests disclosed on Statement 28 are reported on a fully diluted basis as of September 30, 2025.

Part 13, Question 30 – Payments, Distributions, or Withdrawals Credited or Given to Insiders. Any such payments were identified in Statement 4 so as to not duplicate disclosures.

Fill in this information to identify the case:

Debtor Name: In re : ATP Life Science Ventures, L.P.

United States Bankruptcy Court for the: District of Delaware

Case number (if known): 25-12178 (LSS)

☐ Check if this is an amended filing

Official Form 206Sum

Summary of Assets and Liabilities for Non-Individuals 12/15

Part 1: Summary of Assets

1. ***Schedule A/B: Assets–Real and Personal Property*** (Official Form 206A/B)

1a. **Real property:**

Copy line 88 from *Schedule A/B* ..... $ 0.00

1b. **Total personal property:**

Copy line 91A from *Schedule A/B* ..... $ 3,606,347,236.65

1c. **Total of all property:**

Copy line 92 from *Schedule A/B* ..... $ 3,606,347,236.65

Part 2: Summary of Liabilities

2. ***Schedule D: Creditors Who Have Claims Secured by Property*** (Official Form 206D)

Copy the total dollar amount listed in Column A, *Amount of claim*,from line 3 of *Schedule D* ..... $ 0.00

3. ***Schedule E/F: Creditors Who Have Unsecured Claims*** (Official Form 206E/F)

3a. **Total claim amounts of priority unsecured claims:**

Copy the total claims from Part 1 from line 5a of *Schedule E/F* ..... $ 0.00

3b. **Total amount of claims of nonpriority amount of unsecured claims:**

Copy the total of the amount of claims from Part 2 from line 5b of *Schedule E/F* ..... + $ 221,708,538.00

4. **Total liabilities**

Lines 2 + 3a + 3b ..... $ 221,708,538.00

Fill in this information to identify the case:

Debtor Name: In re : ATP Life Science Ventures, L.P.

United States Bankruptcy Court for the: District of Delaware

Case number (if known): 25-12178 (LSS)

☐ Check if this is an amended filing

Official Form 206A/B

Schedule A/B: Assets - Real and Personal Property

12/15

Disclose all property, real and personal, which the debtor owns or in which the debtor has any other legal, equitable, or future interest. Include all property in which the debtor holds rights and powers exercisable for the debtor's own benefit. Also include assets and properties which have no book value, such as fully depreciated assets or assets that were not capitalized. In Schedule A/B, list any executory contracts or unexpired leases. Also list them on Schedule G: Executory Contracts and Unexpired Leases (Official Form 206G).

Be as complete and accurate as possible. If more space is needed, attach a separate sheet to this form. At the top of any pages added, write the debtor's name and case number (if known). Also identify the form and line number to which the additional information applies. If an additional sheet is attached, include the amounts from the attachment in the total for the pertinent part.

For Part 1 through Part 11, list each asset under the appropriate category or attach separate supporting schedules, such as a fixed asset schedule or depreciation schedule, that gives the details for each asset in a particular category. List each asset only once. In valuing the debtor's interest, do not deduct the value of secured claims. See the instructions to understand the terms used in this form.

Part 1: Cash and cash equivalents

1. **Does the debtor have any cash or cash equivalents?**

☐ No. Go to Part 2.

☑ Yes. Fill in the information below.

All cash or cash equivalents owned or controlled by the debtor			Current value of debtor's interest
2. **Cash on hand**			
2.1 None			$
3. **Checking, savings, money market, or financial brokerage accounts** *(Identify all)*			
Name of institution (bank or brokerage firm)	Type of account	Last 4 digits of account number	
3.1 Banc of California	Checking	x6841	$ 14,422,356.33
3.2 J P Morgan	Investment	x2650	$ 2.25
4. **Other cash equivalents** *(Identify all)*			
4.1 None			$
5. **Total of Part 1**			
Add lines 2 through 4 (including amounts on any additional sheets). Copy the total to line 80.			$ 14,422,358.58

Debtor: ATP Life Science Ventures, L.P. Case number *(if known)*: 25-12178

Name

Part 2: Deposits and prepayments

6. **Does the debtor have any deposits or prepayments?**

☑ No. Go to Part 3.

☐ Yes. Fill in the information below.

	Current value of debtor's interest
7. **Deposits, including security deposits and utility deposits** Description, including name of holder of deposit	$
8. **Prepayments, including prepayments on executory contracts, leases, insurance, taxes, and rent** Description, including name of holder of prepayment	$
9. **Total of Part 2.** Add lines 7 through 8. Copy the total to line 81.	$ 0.00

Debtor: ATP Life Science Ventures, L.P. Case number *(if known)*: 25-12178

Name

Part 3: Accounts receivable

10. **Does the debtor have any accounts receivable?**

☑ No. Go to Part 4.

☐ Yes. Fill in the information below.

						Current value of debtor's interest
11. **Accounts receivable**	Description	face amount		doubtful or uncollectible accounts		
11a. 90 days old or less:		$	- $		=..... ➔	$
11b. Over 90 days old:		$	- $		=..... ➔	$

12. **Total of Part 3.**

Current value on lines 11a + 11b = line 12. Copy the total to line 82. $ 0.00

Debtor: ATP Life Science Ventures, L.P. Case number *(if known)*: 25-12178

Name

Part 4: Investments

13. **Does the debtor own any investments?**

☐ No. Go to Part 5.

☑ Yes. Fill in the information below.

		Valuation method used for current value	Current value of debtor's interest
14. **Mutual funds or publicly traded stocks not included in Part 1**			
Name of fund or stock:			
14.1	None		$
15. **Non-publicly traded stock and interests in incorporated and unincorporated businesses, including any interest in an LLC, partnership, or joint venture**			
Name of entity:	% of ownership:		
15.1	See Schedule A/B 15 Attachment		$ 3,552,750,635.00
16. **Government bonds, corporate bonds, and other negotiable and non-negotiable instruments not included in Part 1**			
Describe:			
16.1	None		$

17. **Total of Part 4.**

Add lines 14 through 16. Copy the total to line 83. $ 3,552,750,635.00

Debtor: ATP Life Science Ventures, L.P. Case number *(if known)*: 25-12178

Name

Part 5: Inventory, excluding agriculture assets

18. **Does the debtor own any inventory (excluding agriculture assets)?**

- ☑ No. Go to Part 6.
- ☐ Yes. Fill in the information below.

	General description	Date of the last physical inventory	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
19.	**Raw materials**		$		$
20.	**Work in progress**		$		$
21.	**Finished goods, including goods held for resale**		$		$
22.	**Other inventory or supplies**		$		$

23. **Total of Part 5.**
Add lines 19 through 22. Copy the total to line 84. $ 0.00

24. **Is any of the property listed in Part 5 perishable?**

- ☐ No
- ☐ Yes

25. **Has any of the property listed in Part 5 been purchased within 20 days before the bankruptcy was filed?**

- ☐ No
- ☐ Yes. Description_____ Book value $ _____ Valuation method _____ Current value $ _____

26. **Has any of the property listed in Part 5 been appraised by a professional within the last year?**

- ☐ No
- ☐ Yes

Debtor: ATP Life Science Ventures, L.P. Case number *(if known)*: 25-12178

Name

Part 6: Farming and fishing-related assets (other than titled motor vehicles and land)

27. **Does the debtor own or lease any farming and fishing-related assets (other than titled motor vehicles and land)?**

- ☑ No. Go to Part 7.
- ☐ Yes. Fill in the information below.

General description	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
28. **Crops—either planted or harvested**	$		$
29. **Farm animals** *Examples:* Livestock, poultry, farm-raised fish	$		$
30. **Farm machinery and equipment** (Other than titled motor vehicles)	$		$
31. **Farm and fishing supplies, chemicals, and feed**	$		$
32. **Other farming and fishing-related property not already listed in Part 6**	$		$

33. **Total of Part 6.**
Add lines 28 through 32. Copy the total to line 85. $ 0.00

34. **Is the debtor a member of an agricultural cooperative?**

- ☐ No
- ☐ Yes. Is any of the debtor's property stored at the cooperative?
  - ☐ No
  - ☐ Yes

35. **Has any of the property listed in Part 6 been purchased within 20 days before the bankruptcy was filed?**

- ☐ No
- ☐ Yes. Description_____ Book value $ _____ Valuation method_____ Current value $ _____

36. **Is a depreciation schedule available for any of the property listed in Part 6?**

- ☐ No
- ☐ Yes

37. **Has any of the property listed in Part 6 been appraised by a professional within the last year?**

- ☐ No
- ☐ Yes

Debtor: ATP Life Science Ventures, L.P. Case number *(if known)*: 25-12178

Name

Part 7: Office furniture, fixtures, and equipment; and collectibles

38. **Does the debtor own or lease any office furniture, fixtures, equipment, or collectibles?**

☑ No. Go to Part 8.

☐ Yes. Fill in the information below.

	General description	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
39.	**Office furniture**	$		$
40.	**Office fixtures**	$		$
41.	**Office equipment, including all computer equipment and communication systems equipment and software**	$		$
42.	**Collectibles** *Examples:* Antiques and figurines; paintings,prints, or other artwork; books, pictures, or other art objects; china and crystal; stamp, coin, or baseball card collections; other collections, memorabilia, or collectibles	$		$

43. **Total of Part 7.**
Add lines 39 through 42. Copy the total to line 86. $ 0.00

44. **Is a depreciation schedule available for any of the property listed in Part 7?**

☐ No

☐ Yes

45. **Has any of the property listed in Part 7 been appraised by a professional within the last year?**

☐ No

☐ Yes

Debtor: ATP Life Science Ventures, L.P. Case number *(if known)*: 25-12178

Name

Part 8: Machinery, equipment, and vehicles

46. **Does the debtor own or lease any machinery, equipment, or vehicles?**

- ☑ No. Go to Part 9.
- ☐ Yes. Fill in the information below.

General description Include year, make, model, and identification numbers (i.e., VIN, HIN, or N-number)	**Net book value of debtor's interest** (Where available)	**Valuation method used for current value**	**Current value of debtor's interest**

47. **Automobiles, vans, trucks, motorcycles, trailers, and titled farm vehicles**

_____ $ _____ _____ $ _____

48. **Watercraft, trailers, motors, and related accessories** Examples: Boats, trailers, motors, floating homes, personal watercraft, and fishing vessels

_____ $ _____ _____ $ _____

49. **Aircraft and accessories**

_____ $ _____ _____ $ _____

50. **Other machinery, fixtures, and equipment (excluding farm machinery and equipment)**

_____ $ _____ _____ $ _____

51. **Total of Part 8.**

Add lines 47 through 50. Copy the total to line 87. $ 0.00

52. **Is a depreciation schedule available for any of the property listed in Part 8?**

- ☐ No
- ☐ Yes

53. **Has any of the property listed in Part 8 been appraised by a professional within the last year?**

- ☐ No
- ☐ Yes

Debtor: ATP Life Science Ventures, L.P. Case number *(if known)*: 25-12178

Name

Part 9: Real property

54. **Does the debtor own or lease any real property?**

☑ No. Go to Part 10.

☐ Yes. Fill in the information below.

55. **Any building, other improved real estate, or land which the debtor owns or in which the debtor has an interest**

Description and location of property Include street address or other description such as Assessor Parcel Number (APN), and type of property (for example, acreage, factory, warehouse, apartment or office building), if available.	**Nature and extent of debtor's interest in property**	**Net book value of debtor's interest** (Where available)	**Valuation method used for current value**	**Current value of debtor's interest**
55.1		$		$

56. **Total of Part 9.**

Add the current value on lines 55.1 through 55.6 and entries from any additional sheets. Copy the total to line 88.

$ 0.00

57. **Is a depreciation schedule available for any of the property listed in Part 9?`**

☐ No

☐ Yes

58. **Has any of the property listed in Part 9 been appraised by a professional within the last year?**

☐ No

☐ Yes

Debtor: ATP Life Science Ventures, L.P. Case number *(if known)*: 25-12178

Name

Part 10: Intangibles and intellectual property

59. **Does the debtor have any interests in intangibles or intellectual property?**

- ☑ No. Go to Part 11.
- ☐ Yes. Fill in the information below.

	General description	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
60.	**Patents, copyrights, trademarks, and trade secrets**	$		$
61.	**Internet domain names and websites**	$		$
62.	**Licenses, franchises, and royalties**	$		$
63.	**Customer lists, mailing lists, or other compilations**	$		$
64.	**Other intangibles, or intellectual property**	$		$
65.	**Goodwill**	$		$

66. **Total of Part 10.**
Add lines 60 through 65. Copy the total to line 89. $ 0.00

67. **Do your lists or records include personally identifiable information of customers** (as defined in 11 U.S.C. §§ 101(41A) and 107)**?**

- ☐ No
- ☐ Yes

68. **Is there an amortization or other similar schedule available for any of the property listed in Part 10?**

- ☐ No
- ☐ Yes

69. **Has any of the property listed in Part 10 been appraised by a professional within the last year?**

- ☐ No
- ☐ Yes

Debtor: ATP Life Science Ventures, L.P. Case number *(if known)*: 25-12178

Name

Part 11: All other assets

70. **Does the debtor own any other assets that have not yet been reported on this form?**
Include all interests in executory contracts and unexpired leases not previously reported on this form.

☐ No. Go to Part 12.

☑ Yes. Fill in the information below.

								Current value of debtor's interest
71. **Notes receivable**								
Description (include name of obligor)		Total face amount		doubtful or uncollectible accounts				
71.1	See Schedule A/B 71 Attachment	$	19,654,611.27	- $	0.00	=..... →	$	19,654,611.27
72. **Tax refunds and unused net operating losses (NOLs)**								
Description (for example, federal, state, local)								
72.1	None		Tax year				$	
73. **Interests in insurance policies or annuities**								
73.1	See Global Notes						$	
74. **Causes of action against third parties (whether or not a lawsuit has been filed)**								
74.1	None						$	
	Nature of claim							
	Amount requested	$						
75. **Other contingent and unliquidated claims or causes of action of every nature, including counterclaims of the debtor and rights to set off claims**								
75.1	Shareholder Representative Services LLC solely in its capacity as representative of the Securityholders v. Alexion Pharmaceuticals, Inc., C.A. No. 2020-1069-MTZ, Delaware Chancery Court						$	Contingent, Undetermined
	Nature of claim	IP Litigation						
	Amount requested	$	Undetermined					
76. **Trusts, equitable or future interests in property**								
76.1	None						$	
77. **Other property of any kind not already listed** *Examples*: Season tickets, country club membership								
77.1	See Schedule A/B 77 Attachment						$	19,519,631.80
78. **Total of Part 11.**								
Add lines 71 through 77. Copy the total to line 90.							$	39,174,243.07

79. **Has any of the property listed in Part 11 been appraised by a professional within the last year?**

☑ No

☐ Yes

Debtor: ATP Life Science Ventures, L.P. Case number *(if known)*: 25-12178

Name

Part 12: Summary

In Part 12 copy all of the totals from the earlier parts of the form.

	Type of property	Current value of personal property	Current value of real property
80.	**Cash, cash equivalents, and financial assets.** *Copy line 5, Part 1.*	$ 14,422,358.58	
81.	**Deposits and prepayments.** *Copy line 9, Part 2.*	$ 0.00	
82.	**Accounts receivable.** *Copy line 12, Part 3.*	$ 0.00	
83.	**Investments.** *Copy line 17, Part 4.*	$ 3,552,750,635.00	
84.	**Inventory.** *Copy line 23, Part 5.*	$ 0.00	
85.	**Farming and fishing-related assets.** *Copy line 33, Part 6.*	$ 0.00	
86.	**Office furniture, fixtures, and equipment; and collectibles.** *Copy line 43, Part 7.*	$ 0.00	
87.	**Machinery, equipment, and vehicles.** *Copy line 51, Part 8.*	$ 0.00	
88.	**Real property.** *Copy line 56, Part 9.* ➔		$ 0.00
89.	**Intangibles and intellectual property.** *Copy line 66, Part 10.*	$ 0.00	
90.	**All other assets.** *Copy line 78, Part 11.*	$ 39,174,243.07	
91.	**Total.** Add lines 80 through 90 for each column 91a.	$ 3,606,347,236.65	+ 91b. $ 0.00
92.	**Total of all property on Schedule A/B.** Lines 91a + 91b = 92.		$ 3,606,347,236.65

Fill in this information to identify the case:

Debtor Name: In re : ATP Life Science Ventures, L.P.

United States Bankruptcy Court for the: District of Delaware

Case number (if known): 25-12178 (LSS)

☐ Check if this is an amended filing

Official Form 206D

Schedule D: Creditors Who Have Claims Secured by Property

12/15

Be as complete and accurate as possible.

1. **Do any creditors have claims secured by debtor's property?**
   - ☑ No. Check this box and submit page 1 of this form to the court with debtor's other schedules. Debtor has nothing else to report on this form.
   - ☐ Yes. Fill in all of the information below.

Part 1: List Creditors Who Have Secured Claims

2. **List in alphabetical order all creditors who have secured claims.** If a creditor has more than one secured claim, list the creditor separately for each claim.

	Column A **Amount of claim** Do not deduct the value of collateral.	*Column B* **Value of collateral that supports this claim**

2.1 **Creditor's name**

Creditor's Name

Creditor's mailing address

Notice Name

Street

City State ZIP Code

Country

Creditor's email address, if known

Date debt was incurred

Last 4 digits of account number

Do multiple creditors have an interest in the same property?

- ☐ No
- ☐ Yes. Have you already specified the relative priority?
  - ☐ No. Specify each creditor, including this creditor, and its relative priority.
  - ☐ Yes. The relative priority of creditors is specified on lines

Describe debtor's property that is subject to a lien

$ $

Describe the lien

Is the creditor an insider or related party?

- ☐ No
- ☐ Yes

Is anyone else liable on this claim?

- ☐ No
- ☐ Yes. Fill out *Schedule H: Codebtors(Official Form 206H).*

As of the petition filing date, the claim is: Check all that apply.

- ☐ Contingent
- ☐ Unliquidated
- ☐ Disputed

3. **Total of the dollar amounts from Part 1, Column A, including the amounts from the Additional Page, if any.** $

Part 2: List Others to Be Notified for a Debt Already Listed in Part 1

List in alphabetical order any others who must be notified for a debt already listed in Part 1. Examples of entities that may be listed are collection agencies, assignees of claims listed above, and attorneys for secured creditors.

If no others need to be notified for the debts listed in Part 1, do not fill out or submit this page. If additional pages are needed, copy this page.

Name and address	On which line in Part 1 did you enter the related creditor?	Last 4 digits of account number for this entity
Name	Line _____	
Notice Name		
Street		
City / State / ZIP Code		
Country		

Fill in this information to identify the case:

Debtor Name: In re : ATP Life Science Ventures, L.P.

United States Bankruptcy Court for the: District of Delaware

Case number (if known): 25-12178 (LSS)

☐ Check if this is an amended filing

Official Form 206E/F

Schedule E/F: Creditors Who Have Unsecured Claims 12/15

Be as complete and accurate as possible. Use Part 1 for creditors with PRIORITY unsecured claims and Part 2 for creditors with NONPRIORITY unsecured claims. List the other party to any executory contracts or unexpired leases that could result in a claim. Also list executory contracts on Schedule A/B: Assets - Real and Personal Property (Official Form 206A/B) and on Schedule G: Executory Contracts and Unexpired Leases (Official Form 206G). Number the entries in Parts 1 and 2 in the boxes on the left. If more space is needed for Part 1 or Part 2, fill out and attach the Additional Page of that Part included in this form.

Part 1: List All Creditors with PRIORITY Unsecured Claims

1. **Do any creditors have priority unsecured claims? (See 11 U.S.C. § 507).**

☑ No. Go to Part 2.

☐ Yes. Go to Line 2.

2. **List in alphabetical order all creditors who have unsecured claims that are entitled to priority in whole or in part.** If the debtor has more than 3 creditors with priority unsecured claims, fill out and attach the Additional Page of Part 1.

		Total claim	Priority amount
2.1 **Priority creditor's name and mailing address**	**As of the petition filing date, the claim is:** *Check all that apply.*	$	$

Creditor Name

Creditor's Notice name

Address

City State ZIP Code

Country

☐ Contingent

☐ Unliquidated

☐ Disputed

Basis for the claim:

Date or dates debt was incurred

Last 4 digits of account number

Is the claim subject to offset?

☐ No

☐ Yes

Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) ()

Part 2: List All Creditors with NONPRIORITY Unsecured Claims

3. **List in alphabetical order all of the creditors with nonpriority unsecured claims.** If the debtor has more than 6 creditors with nonpriority unsecured claims, fill out and attach the Additional Page of Part 2.

Amount of claim

3.1 **Nonpriority creditor's name and mailing address**

Aethon Therapeutics, Inc.
Creditor Name

Creditor's Notice name

30-02 48th Avenue
Address

Suite 280

Long Island City | NY | 11101
City | State | ZIP Code

Country

Date or dates debt was incurred

Last 4 digits of account number

As of the petition filing date, the claim is: $ 8,000,000.00
Check all that apply.

☑ Contingent
☑ Unliquidated
☐ Disputed

Basis for the claim:
Intercompany Funding

Is the claim subject to offset?
☐ No
☐ Yes

3.2 **Nonpriority creditor's name and mailing address**

Apertor Pharmaceuticals, Inc.
Creditor Name

Creditor's Notice name

651 Gateway Blvd, Suite 1600
Address

South San Francisco | CA | 94080
City | State | ZIP Code

Country

Date or dates debt was incurred

Last 4 digits of account number

As of the petition filing date, the claim is: $ 21,000,000.00
Check all that apply.

☑ Contingent
☑ Unliquidated
☐ Disputed

Basis for the claim:
Intercompany Funding

Is the claim subject to offset?
☐ No
☐ Yes

Debtor: ATP Life Science Ventures, L.P. Case number *(if known)*: 25-12178

Name

3.3 **Nonpriority creditor's name and mailing address**

Ascidian Therapeutics, Inc.
Creditor Name

Creditor's Notice name

80 Guest Street
Address

4th Floor

Boston | MA | 02135
City | State | ZIP Code

Country

Date or dates debt was incurred

Last 4 digits of account number

As of the petition filing date, the claim is: $ 6,000,000.00
Check all that apply.

☑ Contingent
☑ Unliquidated
☐ Disputed

Basis for the claim:
Intercompany Funding

Is the claim subject to offset?
☐ No
☐ Yes

3.4 **Nonpriority creditor's name and mailing address**

Deep Apple Therapeutics, Inc.
Creditor Name

Creditor's Notice name

651 Gateway Blvd, Suite 1600
Address

South San Francisco | CA | 94080
City | State | ZIP Code

Country

Date or dates debt was incurred

Last 4 digits of account number

As of the petition filing date, the claim is: $ 9,000,000.00
Check all that apply.

☑ Contingent
☑ Unliquidated
☐ Disputed

Basis for the claim:
Intercompany Funding

Is the claim subject to offset?
☐ No
☐ Yes

Debtor: ATP Life Science Ventures, L.P. Case number *(if known)*: 25-12178

Name

3.5 **Nonpriority creditor's name and mailing address**

Evercrisp Therapeutics, Inc.
Creditor Name

Creditor's Notice name

651 Gateway Blvd, Suite 1600
Address

South San Francisco | CA | 94080
City | State | ZIP Code

Country

Date or dates debt was incurred

Last 4 digits of account number

As of the petition filing date, the claim is: $ 49,000,000.00

Check all that apply.

☑ Contingent

☑ Unliquidated

☐ Disputed

Basis for the claim:

Intercompany Funding

Is the claim subject to offset?

☐ No

☐ Yes

3.6 **Nonpriority creditor's name and mailing address**

Galvanize Therapeutics, Inc.
Creditor Name

Creditor's Notice name

3200 Bridge Parkway
Address

Redwood City | CA | 94065
City | State | ZIP Code

Country

Date or dates debt was incurred

Last 4 digits of account number

As of the petition filing date, the claim is: $ 102,585.00

Check all that apply.

☑ Contingent

☑ Unliquidated

☐ Disputed

Basis for the claim:

Intercompany Funding

Is the claim subject to offset?

☐ No

☐ Yes

Debtor: ATP Life Science Ventures, L.P. Case number *(if known)*: 25-12178

Name

3.7 **Nonpriority creditor's name and mailing address**

Initial Therapeutics, Inc.
Creditor Name

Creditor's Notice name

651 Gateway Blvd, Suite 1600
Address

South San Francisco | CA | 94080
City | State | ZIP Code

Country

Date or dates debt was incurred

Last 4 digits of account number

As of the petition filing date, the claim is: $ 21,728,000.00

Check all that apply.

☑ Contingent

☑ Unliquidated

☐ Disputed

Basis for the claim:

Intercompany Funding

Is the claim subject to offset?

☐ No

☐ Yes

3.8 **Nonpriority creditor's name and mailing address**

Marengo Therapeutics, Inc
Creditor Name

Creditor's Notice name

840 Memorial Drive
Address

4th Floor

Cambridge | MA | 02139
City | State | ZIP Code

Country

Date or dates debt was incurred

Last 4 digits of account number

As of the petition filing date, the claim is: $ 33,000,000.00

Check all that apply.

☑ Contingent

☑ Unliquidated

☐ Disputed

Basis for the claim:

Intercompany Funding

Is the claim subject to offset?

☐ No

☐ Yes

Debtor: ATP Life Science Ventures, L.P. Case number *(if known)*: 25-12178

Name

3.9 **Nonpriority creditor's name and mailing address**

Marlinspike Therapeutics, Inc.
Creditor Name

Creditor's Notice name

245 Main Street
Address

12th Floor

Cambridge | MA | 02142
City | State | ZIP Code

Country

Date or dates debt was incurred

Last 4 digits of account number

As of the petition filing date, the claim is: $ 37,275,000.00
Check all that apply.

☑ Contingent
☑ Unliquidated
☐ Disputed

Basis for the claim:
Intercompany Funding

Is the claim subject to offset?
☐ No
☐ Yes

3.10 **Nonpriority creditor's name and mailing address**

Red Queen Therapeutics, Inc.
Creditor Name

Creditor's Notice name

245 Main Street
Address

12th Floor

Cambridge | MA | 02142
City | State | ZIP Code

Country

Date or dates debt was incurred

Last 4 digits of account number

As of the petition filing date, the claim is: $ 23,602,953.00
Check all that apply.

☑ Contingent
☑ Unliquidated
☐ Disputed

Basis for the claim:
Intercompany Funding

Is the claim subject to offset?
☐ No
☐ Yes

Debtor: ATP Life Science Ventures, L.P. (Name) Case number *(if known)*: 25-12178

3.11 **Nonpriority creditor's name and mailing address**

Replicate Bioscience, Inc.
Creditor Name

Creditor's Notice name

11558 Sorrento Valley Road
Address

Suite 6

San Diego | CA | 92121
City | State | ZIP Code

Country

Date or dates debt was incurred

Last 4 digits of account number

As of the petition filing date, the claim is: $ 13,000,000.00
Check all that apply.

☑ Contingent
☑ Unliquidated
☐ Disputed

Basis for the claim:
Intercompany Funding

Is the claim subject to offset?
☐ No
☐ Yes

3.12 **Nonpriority creditor's name and mailing address**

Rigmora Biotech Investor One LP
Creditor Name

Creditor's Notice name

3076, Sir Francis Drakes Highway Road Town
Address

Tortola | | VG1110
City | State | ZIP Code

British Virgin Isl
Country

Date or dates debt was incurred

Last 4 digits of account number

As of the petition filing date, the claim is: $ Undetermined
Check all that apply.

☑ Contingent
☑ Unliquidated
☑ Disputed

Basis for the claim:
Limited Partnership Agreement

Is the claim subject to offset?
☐ No
☐ Yes

Debtor: ATP Life Science Ventures, L.P. Case number *(if known)*: 25-12178

Name

3.13 **Nonpriority creditor's name and mailing address**

Rigmora Biotech Investor Two LP
Creditor Name

Creditor's Notice name

3076, Sir Francis Drakes Highway Road Town
Address

Tortola | State | VG1110
City | State | ZIP Code

British Virgin Isl
Country

Date or dates debt was incurred

Last 4 digits of account number

As of the petition filing date, the claim is: $ Undetermined

Check all that apply.

☑ Contingent

☑ Unliquidated

☑ Disputed

Basis for the claim:

Management Contract

Is the claim subject to offset?

☐ No

☐ Yes

Part 3: List Others to Be Notified About Unsecured Claims

4. **List in alphabetical order any others who must be notified for claims listed in Parts 1 and 2. Examples of entities that may be listed are collection agencies, assignees of claims listed above, and attorneys for unsecured creditors.**
If no others need to be notified for the debts listed in Parts 1 and 2, do not fill out or submit this page. If additional pages are needed, copy the next page.

Name and mailing address	On which line in Part 1 or Part 2 is the related creditor (if any) listed?	Last 4 digits of account number, if any
Name Notice Name Street City State ZIP Code Country	Line ☐ Not Listed.Explain	

Part 4: Total Amounts of the Priority and Nonpriority Unsecured Claims

5. **Add the amounts of priority and nonpriority unsecured claims.**

			Total of claim amounts
5a.	**Total claims from Part 1**	5a.	$ 0.00
5b.	**Total claims from Part 2**	5b. +	$ 221,708,538.00
5c.	**Total of Parts 1 and 2** Lines 5a + 5b = 5c.	5c.	$ 221,708,538.00

Fill in this information to identify the case:

Debtor Name: In re : ATP Life Science Ventures, L.P.

United States Bankruptcy Court for the: District of Delaware

Case number (if known): 25-12178 (LSS)

☐ Check if this is an amended filing

Official Form 206G

Schedule G: Executory Contracts and Unexpired Leases 12/15

Be as complete and accurate as possible. If more space is needed, copy and attach the additional page, numbering the entries consecutively.

1. **Does the debtor have any executory contracts or unexpired leases?**
   - ☐ No. Check this box and file this form with the court with the debtor's other schedules. There is nothing else to report on this form.
   - ☑ Yes. Fill in all of the information below even if the contracts or leases are listed on *Schedule A/B: Assets - Real and Personal Property* (Official Form 206A/B).

2. List all contracts and unexpired leases	State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease
2.1 **State what the contract or lease is for and the nature of the debtor's interest**: Engagement Letter **State the term remaining**: **List the contract number of any government contract**:	B. Riley Restructuring Services, LLC (Name) (Notice Name) 11100 Santa Monica Blvd., Suite 800 (Address) Los Angeles (City) CA (State) 90025 (ZIP Code) (Country)
2.2 **State what the contract or lease is for and the nature of the debtor's interest**: Engagement Letter **State the term remaining**: **List the contract number of any government contract**:	Dechert LLP (Name) (Notice Name) One International Place, 40th Floor 100 Oliver Street (Address) Boston (City) MA (State) 02110-2605 (ZIP Code) (Country)

Debtor: ATP Life Science Ventures, L.P. (Name) Case number *(if known)*: 25-12178

2.3 **State what the contract or lease is for and the nature of the debtor's interest**

Agreement

State the term remaining

List the contract number of any government contract

havenX (Name)

Notice Name

1712 Pioneer Ave, Ste 497 (Address)

Cheyenne (City) WY (State) 82001 (ZIP Code)

Country

2.4 **State what the contract or lease is for and the nature of the debtor's interest**

Contract Signature Page

State the term remaining

List the contract number of any government contract

Larimer Law, PLLC (Name)

Notice Name

1371 Pittsford Mendon Rd (Address)

Mendon (City) NY (State) 14506 (ZIP Code)

Country

2.5 **State what the contract or lease is for and the nature of the debtor's interest**

Letter Agreement re: Engagement of Services

State the term remaining

List the contract number of any government contract

Larimer Law, PLLC (Name)

Notice Name

1371 Pittsford Mendon Rd (Address)

Mendon (City) NY (State) 14506 (ZIP Code)

Country

Debtor: ATP Life Science Ventures, L.P. (Name) Case number *(if known)*: 25-12178

2.6 **State what the contract or lease is for and the nature of the debtor's interest**: Engagement Letter

State the term remaining

List the contract number of any government contract

MME (Name)
(Notice Name)
Gubelstrasse 22, PO Box (Address)
(Address)
Zug (City) (State) CH-6302 (ZIP Code)
China (Country)

2.7 **State what the contract or lease is for and the nature of the debtor's interest**: Signature Page for Client Agreement

State the term remaining

List the contract number of any government contract

Ogier (Cayman) LLP (Name)
(Notice Name)
89 Nexus Way (Address)
Camana Bay (Address)
Grand Cayman (City) (State) KY1-9009 (ZIP Code)
Cayman Islands (Country)

2.8 **State what the contract or lease is for and the nature of the debtor's interest**: Engagement Letter

State the term remaining

List the contract number of any government contract

Ogier (Cayman) LLP (Name)
(Notice Name)
89 Nexus Way (Address)
Camana Bay (Address)
Grand Cayman (City) (State) KY1-9009 (ZIP Code)
Cayman Islands (Country)

Debtor: ATP Life Science Ventures, L.P. Case number *(if known)*: 25-12178

Name

2.9 **State what the contract or lease is for and the nature of the debtor's interest**

Consulting Agreement

State the term remaining

List the contract number of any government contract

Palmier Services Ltd
Name

Notice Name

Troias, 2A
Address

Kaimakli

Nicosia | | 1036
City | State | ZIP Code

Country

2.10 **State what the contract or lease is for and the nature of the debtor's interest**

Consulting Agreement

State the term remaining

List the contract number of any government contract

Palmier Servies Ltd
Name

Notice Name

Troias, 2A
Address

Kaimakli

Nicosia | | 1036
City | State | ZIP Code

Country

2.11 **State what the contract or lease is for and the nature of the debtor's interest**

Consulting Agreement

State the term remaining

List the contract number of any government contract

Palmier Servies Ltd
Name

Notice Name

Troias, 2A
Address

Kaimakli

Nicosia | | 1036
City | State | ZIP Code

Country

Debtor: ATP Life Science Ventures, L.P. (Name) Case number *(if known)*: 25-12178

2.12 **State what the contract or lease is for and the nature of the debtor's interest**: Letter Agreement re: Retainer Agreement for Valuation Services

State the term remaining

List the contract number of any government contract

Pluris Valuation Advisors LLC (Name)
Notice Name
61 Broadway, 1915 (Address)
New York (City) NY (State) 10006 (ZIP Code)
Country

2.13 **State what the contract or lease is for and the nature of the debtor's interest**: Letter Agreement re: Retainer Agreement for Valuation Services

State the term remaining

List the contract number of any government contract

Pluris Valuation Advisors LLC (Name)
Notice Name
61 Broadway, 1915 (Address)
New York (City) NY (State) 10006 (ZIP Code)
Country

2.14 **State what the contract or lease is for and the nature of the debtor's interest**: Signature Page to Case Agreement Statement of Work

State the term remaining

List the contract number of any government contract

TransPerfect Document Management, Inc. (Name)
Notice Name
1717 Main St., Suite 3950 (Address)
Dallas (City) TX (State) 75201 (ZIP Code)
Country

Debtor: ATP Life Science Ventures, L.P. Case number *(if known)*: 25-12178

Name

2.15 **State what the contract or lease is for and the nature of the debtor's interest**

Case Agreement Statement of Work

State the term remaining

List the contract number of any government contract

TransPerfect Document Management, Inc.
Name
David Brill - Director, Strategic Accounts
Notice Name
1717 Main St., Suite 3950
Address
Dallas | TX | 75201
City | State | ZIP Code
Country

2.16 **State what the contract or lease is for and the nature of the debtor's interest**

Case Agreement Statement of Work

State the term remaining

List the contract number of any government contract

TransPerfect Document Management, Inc.
Name
David Brill - Director, Strategic Accounts
Notice Name
1717 Main St., Suite 3950
Address
Dallas | TX | 75201
City | State | ZIP Code
Country

2.17 **State what the contract or lease is for and the nature of the debtor's interest**

Engagement Letter

State the term remaining

List the contract number of any government contract

Walkers
Name
Notice Name
190 Elgin Avenue
Address
George Town
Grand Cayman | | KY1-9009
City | State | ZIP Code
Cayman Islands
Country

Fill in this information to identify the case:

Debtor Name: In re : ATP Life Science Ventures, L.P.

United States Bankruptcy Court for the: District of Delaware

Case number (if known): 25-12178 (LSS)

☐ Check if this is an amended filing

Official Form 206H

Schedule H: Codebtors

12/15

Be as complete and accurate as possible. If more space is needed, copy the Additional Page, numbering the entries consecutively. Attach the Additional Page to this page.

1. **Does the debtor have any codebtors?**

   ☑ No. Check this box and submit this form to the court with the debtor's other schedules. Nothing else needs to be reported on this form.

   ☐ Yes

2. **In Column 1, list as codebtors all of the people or entities who are also liable for any debts listed by the debtor in the schedules of creditors, *Schedules D-G*.** Include all guarantors and co-obligors. In Column 2, identify the creditor to whom the debt is owed and each schedule on which the creditor is listed. If the codebtor is liable on a debt to more than one creditor, list each creditor separately in Column 2.

	Column 1: **Codebtor**		*Column 2:* **Creditor**	
	Name	**Mailing address**	**Name**	*Check all schedules that apply:*
2.1		Street City State ZIP Code Country		☐ D ☐ E/F ☐ G

Fill in this information to identify the case:

Debtor Name: In re : ATP Life Science Ventures, L.P.

United States Bankruptcy Court for the: District of Delaware

Case number (if known): 25-12178 (LSS)

Official Form 202

Declaration Under Penalty of Perjury for Non-Individual Debtors

12/15

An individual who is authorized to act on behalf of a non-individual debtor, such as a corporation or partnership, must sign and submit this form for the schedules of assets and liabilities, any other document that requires a declaration that is not included in the document, and any amendments of those documents. This form must state the individual's position or relationship to the debtor, the identity of the document, and the date. Bankruptcy Rules 1008 and 9011.

WARNING -- Bankruptcy fraud is a serious crime. Making a false statement, concealing property, or obtaining money or property by fraud in connection with a bankruptcy case can result in fines up to $500,000 or imprisonment for up to 20 years, or both. 18 U.S.C. §§ 152, 1341, 1519, and 3571.

Declaration and signature

I am the president, another officer, or an authorized agent of the corporation; a member or an authorized agent of the partnership; or another individual serving as a representative of the debtor in this case.

I have examined the information in the documents checked below and I have a reasonable belief that the information is true and correct:

- ☑ *Schedule A/B: Assets–Real and Personal Property* (Official Form 206A/B)
- ☑ *Schedule D: Creditors Who Have Claims Secured by Property* (Official Form 206D)
- ☑ *Schedule E/F: Creditors Who Have Unsecured Claims* (Official Form 206E/F)
- ☑ *Schedule G: Executory Contracts and Unexpired Leases* (Official Form 206G)
- ☑ *Schedule H: Codebtors* (Official Form 206H)
- ☑ *Summary of Assets and Liabilities for Non-Individuals* (Official Form 206Sum)
- ☐ Amended *Schedule* _____
- ☐ *Chapter 11 or Chapter 9 Cases: List of Creditors Who Have the 20 Largest Unsecured Claims and Are Not Insiders (Official Form 204)*
- ☐ Other document that requires a declaration _____

I declare under penalty of perjury that the foregoing is true and correct.

Executed on 01/30/2026
MM / DD / YYYY

✖ / s / Perry M. Mandarino
Signature of individual signing on behalf of debtor

Perry M. Mandarino
Printed name

Chief Restructuring Officer
Position or relationship to debtor

In re: ATP Life Science Ventures, L.P.
Case No. 25-12178
Schedule A/B 15
Non-publicly traded stock and interests

Name of entity	% of ownership	Valuation method used for current value	Current value of debtor's interest
Aethon Therapeutics, Inc.	77.45%		$17,137,000.00
Apertor Pharmaceuticals, Inc.	84.50%		$28,858,000.00
Apple Tree Life Sciences, Inc.	100.00%		Undetermined
Ascidian Therapeutics, Inc.	84.87%		$138,928,000.00
ATP Research & Development, Inc.	100.00%		Undetermined
Aulos Bioscience, Inc.	69.83%		$65,845,000.00
Braeburn Inc.	83.10%		$2,593,479,004.00
Deep Apple Therapeutics, Inc.	78.65%		$41,876,000.00
Evercrisp Therapeutics, Inc.	75.60%		$23,370,000.00
Galvanize Therapeutics, Inc.	23.18%		$202,525,727.00
Initial Therapeutics, Inc.	80.60%		$42,145,000.00
Marengo Therapeutics, Inc.	84.87%		$201,562,904.00
Marlinspike Therapeutics, Inc.	76.90%		$26,722,000.00
Nereid Therapeutics, Inc.	85.15%		$28,389,000.00
Nine Square Therapeutics, Inc.	87.50%		$51,818,000.00
Red Queen Therapeutics, Inc.	87.00%		$31,184,000.00
Replicate Bioscience, Inc.	84.49%		$58,911,000.00
		TOTAL:	**$3,552,750,635.00**
Note: See Global Notes for Valuation Method used to determine Current Value			

In re: ATP Life Science Ventures, L.P.
Case No. 25-12178
Schedule A/B 71
Notes receivable

Description (include name of obligor)	Total face amount	Doubtful or uncollectible amount	Current value of debtor's interest
Secured Promissory Note - Aethon Therapeutics, Inc.	$2,000,000.00	$0.00	$2,000,000.00
Secured Promissory Note - Apertor Pharmaceuticals, Inc.	$1,251,525.30	$0.00	$1,251,525.30
Secured Promissory Note - ATP Research and Development, Inc.	$6,199,990.00	$0.00	$6,199,990.00
Secured Promissory Note - Evercrisp Biosciences, Inc.	$1,440,778.75	$0.00	$1,440,778.75
Secured Promissory Note - Initial Therapeutics, Inc.	$1,338,492.94	$0.00	$1,338,492.94
Secured Promissory Note - Marlinspike Therapeutics, Inc.	$637,504.18	$0.00	$637,504.18
Secured Promissory Note - Nereid Therapeutics, Inc.	$1,903,540.10	$0.00	$1,903,540.10
Secured Promissory Note - Nine Square Therapeutics, Inc.	$866,780.00	$0.00	$866,780.00
Secured Promissory Note - Red Queen Therapeutics, Inc.	$16,000.00	$0.00	$16,000.00
Secured Promissory Note - Replicate Therapeutics, Inc.	$4,000,000.00	$0.00	$4,000,000.00
TOTALS:	**$19,654,611.27**	**$0.00**	**$19,654,611.27**

In re: ATP Life Science Ventures, L.P.
Case No. 25-12178
Schedule A/B 77
Other property of any kind not already listed

Other property of any kind not already listed	Current value of debtor's interest
Affilate Receivable - Aethon Therapeutics, Inc.	$2,000,000.00
Affilate Receivable - Apertor Pharmaceuticals, Inc.	$1,251,525.30
Affilate Receivable - Ascidian Therapeutics, Inc.	$6,000,000.00
Affilate Receivable - Evercrisp Biosciences, Inc.	$1,440,778.75
Affilate Receivable - Initial Therapeutics, Inc.	$1,338,492.94
Affilate Receivable - Marlinspike Therapeutics, Inc.	$637,504.18
Affilate Receivable - Nereid Therapeutics, Inc.	$1,903,540.10
Affilate Receivable - Nine Square Therapeutics, Inc.	$866,780.00
Affilate Receivable - Red Queen Therapeutics, Inc.	$16,000.00
Affilate Receivable - Replicate Therapeutics, Inc.	$4,000,000.00
Any and all rights under the Limited Partnership Agreement	Undetermined
Any and all rights under the Management Contract	Undetermined
Non-bankruptcy related legal retainer - Elsberg Baker & Maruri PLLC	$47,207.00
Non-bankruptcy related legal retainer - Mishcon De Reya (UK)	$17,803.53
TOTAL:	**$19,519,631.80**